Bray Capital Advisors Astrazeneca PLC Transaction History
Bray Capital Advisors
- $387 Million
- Q2 2024
A detailed history of Bray Capital Advisors transactions in Astrazeneca PLC stock. As of the latest transaction made, Bray Capital Advisors holds 8,500 shares of AZN stock, worth $658,495. This represents 0.17% of its overall portfolio holdings.
Number of Shares
8,500
Previous 8,500
-0.0%
Holding current value
$658,495
Previous $575,000
15.13%
% of portfolio
0.17%
Previous 0.15%
Shares
3 transactions
Others Institutions Holding AZN
# of Institutions
1,334Shares Held
490MCall Options Held
4.99MPut Options Held
3.19M-
Price T Rowe Associates Inc Baltimore, MD64.9MShares$5.03 Billion0.61% of portfolio
-
Primecap Management CO Pasadena, CA42.6MShares$3.3 Billion2.44% of portfolio
-
Wellington Management Group LLP Boston, MA40.6MShares$3.14 Billion0.58% of portfolio
-
Capital International Investors Los Angeles, CA36.7MShares$2.84 Billion0.6% of portfolio
-
Franklin Resources Inc San Mateo, CA17.6MShares$1.36 Billion0.44% of portfolio
About ASTRAZENECA PLC
- Ticker AZN
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 3,099,020,032
- Market Cap $240B
- Description
- AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...